Downregulation of Mcl-1 by daunorubicin pretreatment reverses resistance of breast cancer cells to TNF-related apoptosis-inducing ligand

Biochemical and Biophysical Research Communications

Volumn 422, Issue 1, 2012, Pages 42-47

  Oh, Bora ^a   Park, SoJung ^a   Pak, Jhang Ho ^a   Kim, InKi ^a  

^a Asan Medical Center   (South Korea)

Author keywords

Apoptosis; Breast cancer; Daunorubicin; Mcl 1; TRAIL

Indexed keywords

DAUNORUBICIN; PROTEIN MCL 1; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENCY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE;

ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; DAUNORUBICIN; DNA DAMAGE; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA INTERFERENCE; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84861459578     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.04.093     Document Type: Article

References (32)

1. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., Dixit V.M. The receptor for the cytotoxic ligand TRAIL. Science 1997, 276:111-113.
2. Ashkenazi A., Dixit V.M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 1999, 11:255-260.
3. Pitti R.M., Marsters S.A., Ruppert S., Donahue C.J., Moore A., Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 1996, 271:12687-12690.
4. Van Geelen C.M., de Vries E.G., de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist. Updat. 2004, 7:345-358.
5. Bhojani M.S., Rossu B.D., Rehemtulla A. TRAIL and anti-tumor responses. Cancer Biol. Ther. 2003, 2:S71-78.
6. Koschny R., Walczak H., Ganten T.M. The promise of TRAIL - Potential and risks of a novel anticancer therapy. J. Mol. Med. (Berl) 2007, 85:923-935.
7. Zhang Y., Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol. Cancer Res. 2008, 6:1861-1871.
8. Fisher M.J., Virmani A.K., Wu L., Aplenc R., Harper J.C., Powell S.M., Rebbeck T.R., Sidransky D., Gazdar A.F., El-Deiry W.S. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin. Cancer Res. 2001, 7:1688-1697.
9. Kim K., Fisher M.J., Xu S.Q., el-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000, 6:335-346.
10. Shin M.S., Kim H.S., Lee S.H., Park W.S., Kim S.Y., Park J.Y., Lee J.H., Lee S.K., Lee S.N., Jung S.S., Han J.Y., Kim H., Lee J.Y., Yoo N.J. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res. 2001, 61:4942-4946.
11. Nakshatri H., Rice S.E., Bhat-Nakshatri P. Antitumor agent parthenolide reverses resistance of breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through sustained activation of c-Jun N-terminal kinase. Oncogene 2004, 23:7330-7344.
12. Ryu B.K., Lee M.G., Chi S.G., Kim Y.W., Park J.H. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. 2001, 194:15-19.
13. Okano H., Shiraki K., Inoue H., Kawakita T., Yamanaka T., Deguchi M., Sugimoto K., Sakai T., Ohmori S., Fujikawa K., Murata K., Nakano T. Cellular FLICE/caspase-8-inhibitory protein as a principal regulator of cell death and survival in human hepatocellular carcinoma. Lab. Invest. 2003, 83:1033-1043.
14. Fulda S., Meyer E., Debatin K.M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002, 21:2283-2294.
15. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ho R., Ikegaki N., Brodeur G.M. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001, 61:1314-1319.
16. Daniel P.T., Wieder T., Sturm I., Schulze-Osthoff K. The kiss of death: promises and failures of death receptors and ligands in cancer therapy. Leukemia 2001, 15:1022-1032.
17. Gibson S.B., Oyer R., Spalding A.C., Anderson S.M., Johnson G.L. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell Biol. 2000, 20:205-212.
18. Nimmanapalli R., Perkins C.L., Orlando M., O'Bryan E., Nguyen D., Bhalla K.N. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res. 2001, 61:759-763.
19. Wen J., Ramadevi N., Nguyen D., Perkins C., Worthington E., Bhalla K. Antileukemic drugs increase death receptor 5 levels and enhance Apo-2L-induced apoptosis of human acute leukemia cells. Blood 2000, 96:3900-3906.
20. Keane M.M., Ettenberg S.A., Nau M.M., Russell E.K., Lipkowitz S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 1999, 59:734-741.
21. Lacour S., Hammann A., Wotawa A., Corcos L., Solary E., Dimanche-Boitrel M.T. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis. Cancer Res. 2001, 61:1645-1651.
22. Dumitru C.A., Carpinteiro A., Trarbach T., Hengge U.R., Gulbins E. Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Apoptosis 2007, 12:1533-1541.
23. Kelly M.M., Hoel B.D., Voelkel-Johnson C. Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Cancer Biol. Ther. 2002, 1:520-527.
24. El-Zawahry A., McKillop J., Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 2005, 5:2.
25. Zhang J.H., Chung T.D., Oldenburg K.R. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen 1999, 4:67-73.
26. Mahalingam D., Szegezdi E., Keane M., de Jong S., Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat Rev. 2009, 35:280-288.
27. Adams J.M., Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337.
28. Wirth T., Kuhnel F., Fleischmann-Mundt B., Woller N., Djojosubroto M., Rudolph K.L., Manns M., Zender L., Kubicka S. Telomerase-dependent virotherapy overcomes resistance of hepatocellular carcinomas against chemotherapy and tumor necrosis factor-related apoptosis-inducing ligand by elimination of Mcl-1. Cancer Res. 2005, 65:7393-7402.
29. Han J., Goldstein L.A., Gastman B.R., Rabinowich H. Interrelated roles for Mcl-1 and BIM in regulation of TRAIL-mediated mitochondrial apoptosis. J. Biol. Chem. 2006, 281:10153-10163.
30. Rosato R.R., Almenara J.A., Coe S., Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007, 67:9490-9500.
31. Meng X.W., Lee S.H., Dai H., Loegering D., Yu C., Flatten K., Schneider P., Dai N.T., Kumar S.K., Smith B.D., Karp J.E., Adjei A.A., Kaufmann S.H. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J. Biol. Chem. 2007, 282:29831-29846.
32. Zhong Q., Gao W., Du F., Wang X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 2005, 121:1085-1095.